Capricor Therapeutics Stock Alpha and Beta Analysis
| CAPR Stock | USD 12.79 0.28 2.14% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Capricor Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Capricor Therapeutics over a specified time horizon. Remember, high Capricor Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Capricor Therapeutics' market risk premium analysis include:
Beta 1.26 | Alpha 0.31 | Risk 4.62 | Sharpe Ratio 0.0095 | Expected Return 0.0441 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Capricor |
Capricor Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Capricor Therapeutics market risk premium is the additional return an investor will receive from holding Capricor Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Capricor Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Capricor Therapeutics' performance over market.| α | 0.31 | β | 1.26 |
Capricor Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Capricor Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Capricor Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Capricor Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Capricor Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Capricor Therapeutics shares will generate the highest return on investment. By understating and applying Capricor Therapeutics stock market price indicators, traders can identify Capricor Therapeutics position entry and exit signals to maximize returns.
Capricor Therapeutics Return and Market Media
The median price of Capricor Therapeutics for the period between Fri, Dec 13, 2024 and Thu, Mar 13, 2025 is 14.23 with a coefficient of variation of 6.36. The daily time series for the period is distributed with a sample standard deviation of 0.9, arithmetic mean of 14.14, and mean deviation of 0.73. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Dunbar George W Jr of 8310 shares of Capricor Therapeutics subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Karen Krasney of 7140 shares of Capricor Therapeutics at 5.12 subject to Rule 16b-3 | 01/03/2025 |
3 | Acquisition by Auwaerter Paul Gisbert of 1440 shares of Capricor Therapeutics at 14.96 subject to Rule 16b-3 | 01/06/2025 |
4 | QuidelOrtho Q4 Earnings and Revenues Top Estimates | 02/12/2025 |
5 | Is Capricor Therapeutics, Inc. the Best Small-Cap Growth Stock to Buy Now | 02/25/2025 |
6 | Acquisition by Collier Earl M Jr of 3240 shares of Capricor Therapeutics at 14.96 subject to Rule 16b-3 | 02/28/2025 |
7 | Disposition of 750 shares by Dunbar George W Jr of Capricor Therapeutics at 1. subject to Rule 16b-3 | 03/03/2025 |
8 | Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy | 03/04/2025 |
9 | Capricor Therapeutics, Inc. A Bull Case Theory | 03/06/2025 |
10 | Capricor Therapeutics to Present at Leerinks Global Healthcare Conference 2025 | 03/07/2025 |
11 | Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19 | 03/11/2025 |
About Capricor Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Capricor or other stocks. Alpha measures the amount that position in Capricor Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.1 | 0.0835 | 0.096 | 0.0912 | Revenue Per Share | 0.1 | 0.94 | 1.08 | 1.03 |
Capricor Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Capricor Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Capricor Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Capricor Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Capricor Therapeutics. Please utilize our Beneish M Score to check the likelihood of Capricor Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Capricor Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.